Dermatology and Ophthalmology Kume Clinic
Dermatology and Ophthalmology Kume Clinic
Sakai, Osaka, Japan9 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Recruiting | Phase 3 | 2026-10-06 | NCT07783425 | |
| A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo | Skin and Connective Tissue Diseases, hypopigmentation of the skin, skin disorder, skin pigmentation disorder, vitiligo | Active, not recruiting | Phase 3 | 2026-09-28 | NCT06163326 | |
| A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Recruiting | Phase 2 | 2026-09-25 | NCT07216027 | |
| A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Recruiting | Phase 3 | 2026-09-25 | NCT06807281 | |
| A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema | Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, skin disorder | Recruiting | Phase 3 | 2026-09-25 | NCT06807268 | |
| Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3) | DNA Virus Infections, Infections, Skin Diseases, Viral, Skin and Connective Tissue Diseases, Tumor Virus Infections, common wart, human papilloma virus infection, skin disorder, skin disorder caused by infection, viral infectious disease | Recruiting | Phase 3 | 2026-09-03 | NCT07637734 | |
| A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Enrolling by invitation | Phase 3 | 2026-07-30 | NCT05735483 | |
| A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. | Chronic Disease, Chronic Spontaneous Urticaria, Disease Attributes, Hypersensitivity, Immediate, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Pruritus, Signs and Symptoms, Skin Manifestations, Skin and Connective Tissue Diseases, chronic urticaria, immune system disorder, skin disorder, skin vascular disease, urticaria | Recruiting | Phase 2 | 2026-06-17 | NCT07219615 | |
| Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, psoriasis, skin disorder | Active, not recruiting | Phase 3 | 2026-04-13 | NCT06846541 |